Sentences with phrase «efficacy of treatment of»

Dr. Jain's nominators note that, in sum, his work has provided ``... unprecedented molecular, cellular, anatomical and functional insights into the vascular pathophysiology of tumors, for proposing the seminal hypothesis that antiangiogenic therapy can «normalize» the aberrant vasculature and microenvironment of tumors and thereby improve both delivery and efficacy of treatment of solid tumors.»

Antagonistic analogs of growth hormone - releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study

What is new, however, is recent evidence that we can use this knowledge to assess the efficacy of our treatments of animals with kidney disease or with high blood pressure.

Not exact matches

Rather, it's the no - holds - barred sales practices that Alexion allegedly engaged in — which, in some cases, reportedly led to salespeople bullying doctors into prescribing the drug for patients even when the efficacy of the treatment was unclear.

The downside: New companies will have to answer questions about their efficacy and be able to change consumer behavior, especially if they are introducing new methods of health care that take consumers away from in - person treatment, according to First Round Capital partner Phineas Barnes.

Insurers like Anthem have refused to cover the exorbitantly pricey treatment (around $ 300,000) since the drug's label admits that Exondys hasn't proved its efficacy, making the therapy a roll of the dice for payers and patients alike.

The treatment was approved for the devastating rare disease Duchenne muscular dystrophy but created major divisions within the FDA because it simply hadn't demonstrated a whole lot of efficacy, meaning the pricey therapy is essentially being subjected to a real - world clinical test.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Last year, the FDA approved a pioneering Duchenne treatment from Sarepta Therapeutics (srpt) over the protests of its own scientific advisers who said it lacked proven efficacy.

Though many of these rewetting drops are available over the counter, many were known to cause only temporary relief from signs and symptoms or may not even be an effective treatment and some of these rewetting agents have not been tested for its efficacy scientifically.

For the same reason, it is not easy to prove treatment efficacy by means of controlled, randomized studies, the «gold standard» for evaluating new therapies.

We continually innovate to promote the safety and efficacy of our treatments.

Sensory Integration (SI) is somewhat of an unknown in the medical arena, and understandably so — it is just recently that studies are beginning to demonstrate the true efficacy of treatment.

Lack of efficacy of thickened feeding as treatment for gastroesophageal reflux.

Meta - analyses of studies evaluating these programs show positive effects on the competence, efficacy and psychological health of the parents, as well as on the behaviour of the children.49, 50 A recent implementation study of a strategy for parenting and family support showed that families in the treatment group had far fewer cases of substantiated child maltreatment, abuse injuries and out - of - home placements.51

The efficacy of these treatments for other anxiety disorders in children and adolescents has been supported by multiple randomized controlled trials (e.g., Walkup et al., 2008).

The DfE replied that there is none: 2005 guidance on the matter has been withdrawn by the Coalition, and this at any rate did not mention alternative medicine or efficacy of treatments.

«Until we have further evidence on the efficacy of medical cannabis for the treatment of sleep apnea, and until its safety profile is established, patients should discuss proven treatment options with a licensed medical provider at an accredited sleep facility,» said lead author Dr. Kannan Ramar, professor of medicine in the division of pulmonary and critical care medicine at Mayo Clinic in Rochester, Minnesota.

The trial needs to involve at least 50 people with OCD and a credible control treatment to really test the efficacy of this idea, says Jon Abramowitz, a clinical psychologist at the University of North Carolina at Chapel Hill.

The three - armed trial evaluated the efficacy of chiropractic spinal manipulative therapy (CSMT) in the treatment of migraine versus placebo (sham chiropractic) and control (usual drug treatment).

«The efficacy of this intensive treatment is balanced by more toxicity, mainly haematological but also esophageal and pulmonary.

Researchers conclude that for the treatment of primary insomnia, neurofeedback does not have a specific efficacy beyond unspecific placebo effects.

Now, immunotherapy — a type of treatment that harnesses the patient's immune system to combat the disease — represents the future of cancer treatment, with its efficacy being demonstrated in even the most aggressive types of cancer.

There is no cure for HD and current treatments are of very limited efficacy.

Dr. Rassool says that a clinical trial is planned to test whether low doses of a DNMT inhibitor, decitabine, and an investigational PARP inhibitor, talazoparib, can be safely combined and whether this therapy shows efficacy for AML patients, especially those who can not receive intensive chemotherapy, whose leukemia is resistant to treatment, or who have experienced a relapse after treatment.

The organs - on - chips can then be used to test the efficacy of drug treatments on a particular organ.

The researchers hope that ultimately human trials will prove the efficacy of the OH14 compound in sensitising tumour cells and cancer stem cells to existing drug - based therapies thus disabling tumours from seeding new growth after treatment.

Schlom, of the National Cancer Institute, says the next challenge for researchers is to find ways to combine different immunotherapy drugs into single treatments and measure their efficacy in clinical trials.

These encouraging results in terms of safety and efficacy are paving the way for a new kind of treatment, not only for Still's disease, but other rare inflammatory diseases, too.

Prior studies on the diet have shown potential for alleviating symptoms of the neurodegenerative disease multiple sclerosis, increasing the efficacy of chemotherapy for cancer treatments, and decreasing visceral fat.

The company hopes to launch a second study in mid-2015 to determine the appropriate dose before moving on to test the efficacy of the treatment.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

Following a systematic review of case reports and an FDA safety database, researchers at the Perelman School of Medicine at the University of Pennsylvania are calling for formal controlled investigations into the safety and efficacy of off - label use of the Lariat device, which has never been approved for treatment of this condition.

«We hope that this assessment of the efficacy of currently available migraine therapies helps patients and their physicians utilize treatments that are the most appropriate for them,» said Dr. Silberstein.

Despite a lack of rigorous clinical trials to test safety or efficacy, a ban of the treatment by health authorities, and a lack of peer review by the scientific community, the privately funded Stamina Foundation has been using cultured mesenchymal stem cells that have been exposed to putative conditions that favour neuronal differentiation to treat different diseases in severely or terminally ill patients.

Tekmira siRNAs and ZMapp «are both head and shoulders above everything else in terms of demonstrated efficacy in nonhuman primates,» says Thomas Geisbert, an expert on Ebola virus at The University of Texas Medical Branch at Galveston who has worked on most of the experimental treatments and vaccines under consideration.

Shadi Yaghi, M.D., of Brown University, Providence, R.I., and colleagues analyzed data from 10 stroke centers across the United States to understand the natural history of thrombolysis - related sICH and to focus on the efficacy of various treatments used.

Further trials are planned to document the efficacy and safety of the combination in patients infected with the other HCV genotypes and in particularly vulnerable groups, to enable a public health approach to the treatment of hepatitis C.

Exploiting the same pre-clinical model used for their studies, the researchers are testing the efficacy of this kind of drug candidates against cancer stem cells, and the possibility of identifying combination regimens with standard chemotherapies with minimized toxic effects, with the perspective of their possible application for the treatment of human breast cancer.

This is intended to verify the efficacy of this treatment method, and to help ensure the implementation of dTMS for MS - associated fatigue into routine clinical practice.

NIAID researchers and colleagues sought to confirm the presence of piperaquine - resistant infections in Cambodia by comparing the efficacy of dihydroartemisinin - piperaquine treatment in 204 malaria - afflicted participants aged 2 to 65 years from three provinces in Cambodia with varying levels of artemisinin resistance.

The authors say: «The excellent efficacy of DP for the treatment of malaria in multiple countries and for chemoprevention in our high transmission area suggest that this regimen will offer benefit in many regions in need of improved control measures.»

«RNAi is very promising as a therapy, but the efficacy of the treatment declines over time with each new cell division,» Jose said.

Prof Fortunato Ciardiello from Seconda Università degli Studi di Napoli, Italy, presented results from the CAPRI - Goim study on the efficacy of cetuximab plus FOLFOX chemotherapy as second - line treatment for patients with mCRC that progressed following FOLFIRI chemotherapy and cetuximab.

«All endpoints of efficacy and tolerability favoured treatment with pembrolizumab, suggesting it should become one standard of care for first line treatment of patients with advanced NSCLC and high PD - L1 expression.

Furthermore, the report accuses the British Homeopathic Association (BHA), which had submitted evidence to the panel, of cherry - picking, and even, in one case actively misrepresenting, research into the treatment (a famous study that concluded its findings were «compatible with the notion that the clinical effects of homeopathy are placebo effects» was cited by the BHA as evidence of the treatment's efficacy.)

And while 50 % of patients experienced a relapse of their myeloma, the subsequent treatment showed marked efficacy: 50 % of these patients were alive five years after the relapse.

The goals of Cohort B, for which survival data are not yet complete, were, primarily, to prove pembrolizumab's safety and, secondarily, to explore its efficacy as a first - line treatment.

Biological treatment of psoriasis shows a good efficacy in clinical trials.

Indeed, the same team of researchers has demonstrated the efficacy of a possible new treatment, which has been patented through the CNIC.